25.11.2016 • News

Solvay Wins More Rare Earths Disputes

(c) Pierre Desrosiers/Shutterstock
(c) Pierre Desrosiers/Shutterstock

Solvay has won another two patent cases against affiliates of Neo Performance Materials relating to its range of OPtalys cerium/zirconium mixed oxides products. The Belgian group has been involved in an ongoing dispute over the rare earths with Neo Performance Materials, which was formerly known as Molycorp. Headquartered in Toronto, Canada, Molycorp emerged from Chapter 11 bankruptcy protection on Aug. 31.

Courts in Germany and China have confirmed the validity of a key Solvay patent. On Oct. 25, the German Federal Patent Court accepted a version of the patent, which had expired in June 2016, from which only “economically irrelevant” binary products were excluded. Solvay said it will now pursue the corresponding infringement procedure in the Düsseldorf district court, which could entitle it to further damages.

Meanwhile, on Oct. 20, the Chinese Patent Reexamination Board fully rejected the move by Neo affiliate Zibo Jiahua New Materials Resources to invalidate Solvay’s patent in China. Both decisions are subject to appeal. Solvay also sued Neo in the UK earlier this year, claiming infringement of a patent held by its subsidiary Anan Kasei on ceric oxide products.

Rare earth oxides are used in automotive catalysts to abate noxious gases from engine exhausts. Increasingly strict air quality standards are requiring ever more complex formulated rare earth oxides as a result.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read